2. Cell Cycle/DNA Damage Anti-infection Autophagy Apoptosis
  3. Topoisomerase Bacterial Autophagy Apoptosis
  4. Etoposide phosphate

Etoposide phosphate  (Synonyms: BMY-40481)

Cat. No.: HY-13630 Purity: 96.66%
COA Handling Instructions

Molarity Calculator

Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.

For research use only. We do not sell to patients.

Etoposide phosphate Chemical Structure

Etoposide phosphate Chemical Structure

CAS No. : 117091-64-2

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in Water
ready for reconstitution
 USD 103 In-stock
Solution
10 mM * 1 mL in Water USD 103 In-stock
Solid
5 mg USD 70 In-stock
10 mg USD 110 In-stock
25 mg USD 220 In-stock
50 mg USD 350 In-stock
100 mg USD 520 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 100 publication(s) in Google Scholar

Other Forms of Etoposide phosphate:

Etoposide phosphate Related Antibodies

Top Publications Citing Use of Products

81 Publications Citing Use of MCE Etoposide phosphate

WB
RT-PCR
IF
Proliferation Assay
Cell Viability Assay

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Feb 2.  [Abstract]

    Etoposide (VP16; 5 mg/kg; s.c.; every two days for 8 days) strongly suppresses tumor growth in mice.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Mar 1;rgad007.  [Abstract]

    Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    BCL6 mRNA expression in Etoposide (ETO)-resistant and -sensitive cells. Cells are treated with Etoposide at their respective 1/2 IC50s for 24 hr.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide activated mTOR signaling components in Etoposide-resistant Capan-2 and PANC28 cells. Cells were treated with etoposide at their respective 1/2 IC50s for 6 or 12 hr. A long-term treatment with Etoposide activated mTOR signaling components in ETO-resistant cells. Capan-2 and PANC28 cells are treated with 10 μM Etoposide for 2 or 4 days.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Cell sensitivity to Etoposide (ETO). Cancer cells are treated with etoposide at gradient concentrations for 48 hr.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide induced BCL6 protein expression in a time-dependent manner. ETO-resistant or -sensitive cells are treated with etoposide at their respective 1/4 IC50s for 2, 4, or 6 days.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    STAT1 protein and its phosphorylation levels by immunoblotting analysis. Etoposide (ETO)-resistant and -sensitive cells are treated with Etoposide at their respective 1/2 IC50s for indicated time points.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64.  [Abstract]

    FISH of telomeres on metaphase spreads to detect chromosome end-to-end fusions in 6 kb-HeLa treated with VP-16. Control (Scr) or cGAS-depleted cells (gcGAS-1, gcGAS-2) are either harvested immediately following treatment (VP-16, 2 μM, 1 h) or released for 4 h (Release 4 h) during mitosis.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Mar 12;12(3):265.  [Abstract]

    Inhibition of PRDX1 increased the sensitivity of HCT116 cells to Etoposide-induced apoptosis: HCT116 cells infected with lentivirus expressing the indicated shRNAs were treated with 50 μM Etoposide for 0-6 h.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage- and oxidation stress-induced p53 acetylation at K382. Cells are incubated with 50 µM Etoposide (Eto) for 5 h.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage‐ and oxidation stress‐triggered increase of CDKN1A and PUMA. Cells are incubated with 50 µM Etoposide (Eto) for 6 h.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Hepatology. 2020 May;71(5):1660-1677.  [Abstract]

    Exposure to Etoposide (Eto), another DNA-damaging agent, induces PDIA3P1 expression, suggesting that PDIA3P1 may be up-regulated by DNA-damaging agents.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    Fibroblasts and HT-1080 cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 2, 4, 8, 16, 24 and 36 h.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide, an obvious increased green focus of RAD51 is observed in the treated fibroblasts using immunofluorescence (IF) staining.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 4 h, western blots (WB) shows elevated expression of γH2AX, a marker of double-strand breaks (DSBs), in the Etoposide group.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2020 Nov 6;12(11):e12525.  [Abstract]

    Immunoblot of PARP1 cleavage of PeTa cells after 6 days of indicated treatment. Etoposide (10 μM; for 24 h) serves as positive control for apoptosis, and H3 serves as loading control.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Aging Cell. 2020 Jul;19(7):e13171.  [Abstract]

    RPE p16‐mCherry cells were treated with DMSO, Etoposide (20 μM), H2O2 (200 μM), or serum starved for 24 hr.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Leuk Lymphoma. 2018 Jan;59(1):162-170.  [Abstract]

    WT1 and caspase-3 protein levels are detected in two primary AML blasts treated with 100 μM Eto for 24 h.

    Etoposide phosphate purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54.  [Abstract]

    Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM RAD001. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.

    IC50 & Target[1]

    Topoisomerase II

     

    In Vitro

    Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule[1].
    Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50 values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[2].
    Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Etoposide phosphate Related Antibodies

    Cell Viability Assay[2]

    Cell Line: FBXW+/+, FBXW-/- and p53-/- cell
    Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
    Incubation Time: 72 hours
    Result: Inhibited HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth as a concentration manner.

    Western Blot Analysis[2]

    Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
    Concentration: 25 μM
    Incubation Time: 6 hours
    Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.
    In Vivo

    Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female CD-1 mice[3]
    Dosage: 50, 100, or 150 mg/kg
    Administration: Intravenous injection; single dose
    Result: Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).
    Clinical Trial
    Molecular Weight

    668.54

    Formula

    C29H33O16P
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(OP(O)(O)=O)C(OC)=C7)[C@]21[H]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (149.58 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 100 mg/mL (149.58 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.4958 mL 7.4790 mL 14.9580 mL
    5 mM 0.2992 mL 1.4958 mL 2.9916 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (149.58 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.4958 mL 7.4790 mL 14.9580 mL 37.3949 mL
    5 mM 0.2992 mL 1.4958 mL 2.9916 mL 7.4790 mL
    10 mM 0.1496 mL 0.7479 mL 1.4958 mL 3.7395 mL
    15 mM 0.0997 mL 0.4986 mL 0.9972 mL 2.4930 mL
    20 mM 0.0748 mL 0.3739 mL 0.7479 mL 1.8697 mL
    25 mM 0.0598 mL 0.2992 mL 0.5983 mL 1.4958 mL
    30 mM 0.0499 mL 0.2493 mL 0.4986 mL 1.2465 mL
    40 mM 0.0374 mL 0.1870 mL 0.3739 mL 0.9349 mL
    50 mM 0.0299 mL 0.1496 mL 0.2992 mL 0.7479 mL
    60 mM 0.0249 mL 0.1246 mL 0.2493 mL 0.6232 mL
    80 mM 0.0187 mL 0.0935 mL 0.1870 mL 0.4674 mL
    100 mM 0.0150 mL 0.0748 mL 0.1496 mL 0.3739 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Etoposide phosphate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Etoposide117091-64-2BMY-40481BMY40481BMY 40481TopoisomeraseBacterialAutophagyApoptosisHCT116prodrugFBXWp53anti-cancerchemotherapyapoptosisP388leukemiaperipheralneuropathyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Etoposide phosphate
    Cat. No.:
    HY-13630
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.